189 related articles for article (PubMed ID: 25872980)
1. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
2. 'Turn On/Off' fluorescence probe for the screening of unactivated Bruton's tyrosine kinase.
Kawahata W; Asami T; Fujii I; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2141-5. PubMed ID: 25843639
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
4. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase as a drug discovery target.
Pan Z
Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
[TBL] [Abstract][Full Text] [Related]
6. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
7. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
8. Ability of Bruton's Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling.
Bender AT; Gardberg A; Pereira A; Johnson T; Wu Y; Grenningloh R; Head J; Morandi F; Haselmayer P; Liu-Bujalski L
Mol Pharmacol; 2017 Mar; 91(3):208-219. PubMed ID: 28062735
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel 7-substituted 3-(4-phenoxyphenyl)thieno[3,2-c]pyridin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors.
Xin M; Zhao X; Huang W; Jin Q; Wu G; Wang Y; Tang F; Xiang H
Bioorg Med Chem; 2015 Oct; 23(19):6250-7. PubMed ID: 26344595
[TBL] [Abstract][Full Text] [Related]
11. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
12. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA-Encoded Chemical Library.
Cuozzo JW; Centrella PA; Gikunju D; Habeshian S; Hupp CD; Keefe AD; Sigel EA; Soutter HH; Thomson HA; Zhang Y; Clark MA
Chembiochem; 2017 May; 18(9):864-871. PubMed ID: 28056160
[TBL] [Abstract][Full Text] [Related]
14. Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Shi Q; Tebben A; Dyckman AJ; Li H; Liu C; Lin J; Spergel S; Burke JR; McIntyre KW; Olini GC; Strnad J; Surti N; Muckelbauer JK; Chang C; An Y; Cheng L; Ruan Q; Leftheris K; Carter PH; Tino J; De Lucca GV
Bioorg Med Chem Lett; 2014 May; 24(9):2206-11. PubMed ID: 24685542
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
16. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
17. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
18. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of novel pyrimidine analogs as highly selective, non-covalent BTK inhibitors.
Kawahata W; Asami T; Irie T; Sawa M
Bioorg Med Chem Lett; 2018 Jan; 28(2):145-151. PubMed ID: 29198867
[TBL] [Abstract][Full Text] [Related]
20. Three mechanistically distinct kinase assays compared: Measurement of intrinsic ATPase activity identified the most comprehensive set of ITK inhibitors.
Kashem MA; Nelson RM; Yingling JD; Pullen SS; Prokopowicz AS; Jones JW; Wolak JP; Rogers GR; Morelock MM; Snow RJ; Homon CA; Jakes S
J Biomol Screen; 2007 Feb; 12(1):70-83. PubMed ID: 17166826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
